Skip to main content
Clinical Trials/EUCTR2007-002940-86-BE
EUCTR2007-002940-86-BE
Active, not recruiting
Not Applicable

Sepsis, Endothelial function, and Lipids in critically ill patients with Liver Failure (SELLIFA). Nutritional sub-study : Randomized controlled trial comparing the tolerance on lipid metabolism and safety of isocaloric parenteral nutrition with enteral nutrition. - SELLIFA nutritional trial

Cliniques Universitaires Saint-Luc – Université catholique de Louvain0 sitesJuly 26, 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
iver failure, Liver cirrhosis, critical illness, total nutritional support
Sponsor
Cliniques Universitaires Saint-Luc – Université catholique de Louvain
Status
Active, not recruiting
Last Updated
11 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
July 26, 2007
End Date
TBD
Last Updated
11 years ago
Study Type
Interventional clinical trial of medicinal product
Sex
All

Investigators

Sponsor
Cliniques Universitaires Saint-Luc – Université catholique de Louvain

Eligibility Criteria

Inclusion Criteria

  • \- All consecutive patients with a diagnosis of chronic liver failure ;
  • \- Adult patient aged 18 years or above, and less than 85 ;
  • \- Admission to the ICU for an expected period of \> 24 hours;
  • \- Planned total nutritional support;
  • \- Informed consent of the patient or nearest relative.
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1\.2 Adults (18\-64 years) yes
  • F.1\.2\.1 Number of subjects for this age range
  • F.1\.3 Elderly (\>\=65 years) yes

Exclusion Criteria

  • \- Absolute contra\-indications to enteral nutrition : total mechanical ileus, persistent vomiting, high output fistulas, uncertain gastrointestinal anastomosis ;
  • \- Absolute contra\-indications to parenteral nutrition : severe hypertriglyceridemia more than 6 mmol/l (545 mg/dL), severe diabetic ketoacidosis ;
  • \- Age less than 18 years and more than 85 ;
  • \- Pregnancy, including HELLP syndrome ;
  • \- Active malignancy with metastases (localised hepatocellular carcinoma is not an exclusion criteria);
  • \- Systemic chemotherapy in the last 4 weeks (trans\-arterial chemo\-embolisation for localised hepatocellular carcinoma is not an exclusion criteria) ;
  • \- Acquired immunodeficiency syndrome and antiretroviral therapy

Outcomes

Primary Outcomes

Not specified

Similar Trials